Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD123-4-1BB zeta CAR-NK cells
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD123-4-1BB zeta CAR-NK cells are an experimental adoptive cell therapy consisting of primary human natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) targeting CD123 (interleukin-3 receptor alpha), an antigen highly expressed on acute myeloid leukemia (AML) cells and leukemic stem cells. The CAR construct utilizes a CD123-specific single-chain variable fragment (scFv) linked to a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling domain. This therapy aims to redirect NK cell cytotoxicity specifically toward AML cells while leveraging the innate safety profile of NK cells compared to T cells. Research indicates these cells exhibit antigen-specific anti-leukemic activity in vitro and in vivo, though persistence may be limited without additional cytokine support like IL-15.
- Other names
- anti-CD123-4-1BB-CD3zeta CAR-NK cellsanti-CD-123-4-1BB-CD3zeta CAR-NK cellsanti-CD 123-4-1BB-CD3zeta CAR-NK cellsCD123-targeted 4-1BB-zeta CAR-NK cellsCD-123-targeted 4-1BB-zeta CAR-NK cellsCD 123-targeted 4-1BB-zeta CAR-NK cells
02
Targets
IL3RA (Interleukin 3 Receptor)CD247 (T-cell surface glycoprotein CD3 epsilon chain)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on CD123-4-1BB zeta CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD123-4-1BB zeta CAR-NK cells.